Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470496 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4765360 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL28781368 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL28472787 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4361492 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4080844 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL30475134 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL2691990 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4255348 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL2691404 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4614649-A1 | ELECTROLYTIC SOLUTION FOR LITHIUM ION SECONDARY BATTERIES, AND LITHIUM ION SECONDARY BATTERY | Kyocera Corporation (JP) | 2025-09-10 | — | — | EP | claimed |
| EP-4611105-A1 | NONAQUEOUS ELECTROLYTE AND CLAY-TYPE LITHIUM ION SECONDARY BATTERY USING SAME | Kyocera Corporation (JP) | 2025-09-03 | — | — | EP | claimed |
| EP-4611091-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM-ION SECONDARY BATTERY USING SAME | Kyocera Corporation (JP) | 2025-09-03 | — | — | EP | claimed |
| CN-120092348-A | Nonaqueous electrolyte solution and lithium ion secondary battery using same | 京瓷株式会社 | 2025-06-03 | — | — | CN | claimed |
| CN-120092347-A | Nonaqueous electrolyte and clay-type lithium ion secondary battery using same | 京瓷株式会社 | 2025-06-03 | — | — | CN | claimed |
| CN-119386497-A | Shunt-in-situ matrix purification liquid-liquid electric extraction device, method and application | 南方医科大学 | 2025-02-07 | — | — | CN | claimed |
| WO-2024096043-A1 | ELECTROLYTIC SOLUTION FOR LITHIUM ION SECONDARY BATTERIES, AND LITHIUM ION SECONDARY BATTERY | 京セラ株式会社 | 2024-05-10 | — | — | WO | claimed |
| WO-2024090573-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM-ION SECONDARY BATTERY USING SAME | 京セラ株式会社 | 2024-05-02 | — | — | WO | claimed |
| WO-2024090574-A1 | NONAQUEOUS ELECTROLYTE AND CLAY-TYPE LITHIUM ION SECONDARY BATTERY USING SAME | 京セラ株式会社 | 2024-05-02 | — | — | WO | claimed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | claimed |
| CN-100404533-C | New quinuclidine amide derivatives | ALMIRALL PRODESFARMA AG (CH) | 2008-07-23 | — | — | CN | claimed |
| CN-100363363-C | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL PRODESFARMA SA (CH) | 2008-01-23 | — | — | CN | claimed |
| CN-1930158-A | New quaternized quinuclidine esters | ALMIRALL PRODESFARMA SA (ES) | 2007-03-14 | — | — | CN | claimed |
| EP-1711183-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-10-18 | — | — | EP | claimed |
| CN-1250545-C | Novel quinuclidine derivatives and pharmaceutical compositions containing them | ALMIRALL PRODESFARMA AG (CH) | 2006-04-12 | — | — | CN | claimed |
| CN-1678610-A | New quinuclidine amide derivatives | ALMIRALL PRODESFARMA AG (CH) | 2005-10-05 | — | — | CN | claimed |
| CN-1675206-A | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL PRODESFARMA SA (CH) | 2005-09-28 | — | — | CN | claimed |
| WO-2005067537-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-28 | — | — | WO | claimed |
| CN-1487938-A | Quinuclidine derivatives and their use as M3 antagonists | ������ҩ������˾ | 2004-04-07 | — | — | CN | claimed |
| US-3983015-A | Electrochemical fluorination using excess current | PHILLIPS PETROLEUM COMPANY (US) | 1976-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | CES2 3503/4885NAAA 1540/4885EPHX1 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.